Objective: to study the efficacy of intravenous magnesium sulfate and intravenous salbutamol in the treatment of severe asthma in children.
responsiveness of airways, and recurring episodes of wheezing, dyspnea, tightness in the chest, and cough (especially night and morning cough). The prognosis for asthma depends on the levels of obstruction and bronchial hyperresponsiveness. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] During the last few decades, the prevalence of asthma in childhood has increased worldwide. This is probably a consequence of (i) increase in diagnoses; (ii) improvement in understanding of the pathophysiology of asthma; (iii) enhancement of therapeutic resources; and (iv) dissemination of the guidelines of international associations of studies on asthma. 7, 12 In the United States, each year 4.8 million cases of asthma in children are reported. In Europe, from 1981 to 1994, the prevalence of asthma increased from 3 to 7%. In the city of Porto Alegre, southern Brazil, the prevalence of active asthma was reported at 22% for school children aged 10 to 18 years. Santana et al., while carrying out a study at a Pediatric ICU in Porto Alegre, reported that acute severe asthma was the main clinical reason for hospital admission (7.3% of hospitalizations per year at the service). 13, 14 The treatment for bronchial obstruction should be started with oxygen at concentrations that will maintain arterial hemoglobin saturation (SaO 2 ) above 90% and reduce respiratory distress. 2 At the same time, it is important to administer bronchodilators (beta-adrenergics by nebulization) and antiinflammatories (corticoids) in addition to therapeutic measures aimed at correcting hydration and compensating acidosis. 15, 16 In more resistant cases, it is possible to use adjunct therapies such as nebulized ipratropium bromide, intravenous aminophylline, and intravenous beta-adrenergics by continuous infusion. 2, 16 Studies have reported treatment failure of up to 15% in children with severe asthma. The possible factors involved are (i) difficulties of diagnosis; (ii) underestimation of severity; (iii) therapeutic plans poorly elaborated; (iv) inadequacy of treatment; and (v) failure to control attacks. Conversely, early and aggressive treatment can be useful in reverting attacks, favoring better prognosis for the patient. Several drugs have been suggested as alternative treatments for management of acute asthma, most importantly, intravenous salbutamol and magnesium sulfate. 1, 2, 5, 11, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Intravenous infusion of beta-2 agonists, including salbutamol, can cause rapid bronchodilation, stimulate mucociliary transport, and modulate release of inflammatory mediators from mastocytes; in this sense, beta-2 agonists have been widely employed in treatment of asthma at Pediatric ICUs. Due to potential adverse effects of these drugs, indication should observe certain criteria. Salbutamol is indicated in cases of progressive retention of CO 2 , poor clinical response to conventional treatment, and signs of respiratory failure; in other words, situations that require mechanical ventilation. 9, 21, [28] [29] [30] Magnesium sulfate seemingly represents a safe and benign alternative for cases of bronchial obstruction more resistant to conventional treatment. The main effects of magnesium sulfate include decrease in airway resistance, increase in final expiratory volume in one minute, increase in forced vital capacity, and decrease in dyspnea and respiratory frequency. 27, [31] [32] [33] [34] [35] [36] [37] [38] Bronchodilation following administration of magnesium sulfate is a result of modulation of the movement of calcium ion, of decrease in release of acetylcholine at nerve terminals, and of sedative action, in addition to inhibition of release of histamine and to direct inhibition of smooth musculature contraction. The fact that magnesium sulfate acts promptly after administration indicates that it can be an important adjunct in cases of bronchial obstruction at emergency units. 27 Our objective is to assess efficacy and safety of early, intravenous administration of magnesium sulfate and salbutamol for treatment of children admitted to emergency units due to acute asthma.
Patients and methods
We carried out a randomized, double-masked, placebocontrolled study between April 01, 1997 and September 30, 1998. The study was carried out at the Special Pediatric Care Unit (SPCU) of the Hospital São Lucas, Teaching Hospital of the Pontifícia Universidade Católica do Rio Grande do Sul (HSL-PUCRS). Our study was approved by the Research Ethics Committee of the HSL-PUCRS. Informed consent was obtained from the parents or guardians of all patients in the study population.
The selected sample included children presenting with attacks of severe acute asthma refractory to treatment at the outpatient clinic (three nebulizations with beta-agonist in one hour), and who were admitted to the Special Pediatric Care Unit between 7 a.m. and 7 p.m., aged older than 2 and younger than 13 years. Clinical symptoms for diagnosis of severe asthma were wheezing; intercostal, subcostal, and sternal muscle retraction; and use of accessory muscles. These symptoms were considered in association with absolute signs of respiratory failure related to hypoxemia following bronchial obstruction, such as cyanosis, loss of conscience, or chest silent at auscultation. Clinical history (previous attacks, positive response to antiasthmatic treatment, hospitalizations due to bronchial obstruction), previous diagnosis, and family history (history of acute asthma) of these patients were also considered.
Criteria for exclusion of patients from the population were (i) other pneumopathy or cardiopathy at hospital admission; (ii) family history of supraventricular tachycardia, diabetes mellitus, or glucose intolerance; (iii) delay in collection of preestablished laboratory exams; (iv) delay in administration of studied drugs; (v) significant clinical deterioration resulting in transfer to the Pediatric ICU or immediate endotracheal intubation and, thus, preventing the patient from participating in the study; and (vi) parents or guardians refusing to give informed consent.
All patients with severe asthma were submitted to routine therapeutic measures upon admission to the SPCU of the HSL-PUCRS. These measures include intravenous hydration, oxygen, nebulized phenoterol or salbutamol (0.15 mg/kg/dose every 30 minutes), and intravenous hydrocortisone (5 mg/kg/dose). All medications were administered at equal intervals and same dosage.
In addition to the conventional treatment, patients were randomly submitted to receiving one of three intravenous infusions with identical characteristics (odor, color, aspect); the actual composition of the infusion was known only by the nurse. The infusions administered were: (i) magnesium sulfate at 2.5 mg/kg/min for 20 minutes, diluted in saline solution for a total dose of 50 mg/kg considering a maximum of 2 g (1 ml/kg/hour drip); (ii) salbutamol at 1 mg/kg/minute for 20 minutes, diluted in saline solution for a total dose of 20 mg/kg (1 ml/kg/h drip); (iii) saline solution (placebo), intravenous and using 1 ml/kg/h drip (controls).
All patients were continuously monitored for their vital signs (noninvasive arterial pressure, hemoglobin saturation, cardiac and respiratory frequency). Vital signs were monitored and registered prior to, during, and up to 1 hour after administration of the drugs. Serum dosages of calcium, potassium, and magnesium and arterial gasometries were collected before and one hour after administration of drugs. We followed-up hospitalization of each patient without influencing therapeutics or medical prescriptions.
Continuous quantitative variables were expressed by measures of central tendency (average and median) and dispersion (standard deviation), whereas categorical variables were expressed in percentage (%) or in descriptive form. The level of significance was of 5% (P less than 0.05). Groups were compared using Student's t test for assessment of averages of continuous variables. The chi-square test with Yates' correction or Fisher's exact test were used to compare the categorical variables. We employed ANOVA for comparative analysis of the three population groups.
Results
During the study period, a total of 2,868 children were admitted to the SPCU of the HSL-PUCRS, out of which 186 (6.5%) patients were admitted due to acute asthma. Out of these 186 patients, 96 were hospitalized at night. Of the remaining 90 patients, 24 (26.6%) were excluded for being younger than 2 years, and four because their parents or guardians did not consent to participate in the study. In addition, other 12 (13.3%) patients were considered losses for various reasons.
All 50 patients in our population presented with wheezing, retraction of the fourchette or sternal muscle, use of accessory muscle, and dyspnea. The more severe cases were associated with cyanosis, alteration in conscience level, or chest silent to auscultation (decreased vesicular murmur). Some patients presented with cough and difficulty to speak or swallow. All patients were submitted to conventional antiasthmatic treatment.
The age average of patients was 4.5 (± 2.4) years with a predominance of the female sex (53%). Out of the total population, 32 (64%) patients had previous family history of asthma, 26 (52%) of smoking, and 18 (36%) of atopia. Assessment of hospitalizations due to acute asthma indicated that 18 (36%) patients had already been admitted to pediatric observation units, 11 (22%) to nurseries, and 8 (16%) to Pediatric ICUs. The main cause for attacks of bronchial obstructions in our patients was upper airway infection (62%).
Assessment of demographic characteristics, of personal history, and of family history associated with asthma did not indicate statistically significant differences between the three randomized groups (Table 1) .
Vital signs and serum magnesium, calcium, and potassium before administration of the studied drugs also did not indicate statistically significant differences between the three groups ( Table 2 ). This corroborates the homogeneity of the population. We observed a significant decrease in systolic arterial pressure (SAP) during infusion of magnesium sulfate, with patients returning to normal levels after one hour. As expected, this group presented a significant increase in serum levels of magnesium. The intravenous salbutamol group presented a significant decrease in respiratory frequency and increase in SAP during infusion; the latter returning to previous levels in one hour. It is important to underscore that patients in the salbutamol group did not present significant alterations in the averages of cardiac frequencies during or after the infusion. However, during the postinfusion period, we observed a significant decrease in serum potassium levels and a decrease in respiratory frequency.
Before the administration of the studied drugs, all three groups were arranged with children presenting acute asthma of similar severity, according to respiratory acidosis and decrease in levels of PaCO 2 . Nonetheless, in the magnesium sulfate and salbutamol groups, we observed a tendency to normalization of arterial gasometry (Table 3) . Respiratory acidosis was significantly more persistent in the placebo group than in the other two groups. Table 4 presents the duration and quantity of conventional treatment administered to our population. In comparison to controls, the salbutamol group had less nebulizations with bronchodilators, less nebulizations per day of hospital stay, and shorter duration of oxygentherapy.
The adverse effects of studied drugs were not frequent. We observed tachycardia in 5 (29.4%) salbutamol patients Controlled study on intravenous magnesium sulfate... -Santana JC et alii and in 3 (17.6%) magnesium sulfate patients. The most frequent clinical complications were pneumonia (28%), sinusitis (18%), and otitis (14%). The use of mechanical ventilation was required in 5 (10%) patients, out of which 2 (12%) were from the magnesium sulfate group and 3 (19%) from the placebo group. There were no statistically significant differences in relation to hospital stay of the study groups. All patients were discharged from the hospital.
Discussion
We observed that out of the 2,868 children admitted to our services at the HSL, 186 (6.5%) presented clinical status of acute asthma. This result is similar to those of other studies. 1, 12, 28, [39] [40] [41] [42] Assessment of age, weight, and sex indicated that our population was homogeneous and, moreover, that it presented characteristics similar to those of other clinical trials with asthmatic children. Even after being randomized, all three groups remained with similar demographic characteristics without statistically significant differences. Most studies have reported that children with severe acute asthma present an age average between one and six years.
Currently, the discussions on this infirmity indicate that it is very difficult to establish asthma diagnosis before two years of age. 2, 5, 20, [42] [43] [44] [45] Comparison of clinical characteristics related to personal and family history of asthma of all three groups indicated that results were also similar to those found in the literature. 1, 2, 4, 6, 11, 13, 16, 18, 20, 27, 37, 42, 43, [46] [47] [48] [49] [50] [51] [52] The vital signs of patients in all three groups were similar before administration of the drugs, indicating the same clinical status of severe asthma. In the magnesium sulfate group, we observed a decrease in SAP during infusion and increase in SAP one hour after infusion. The average SAP for this group presented a statistically significant difference in relation to controls (108 mmHg and 97 mmHg, respectively; P=0.01). However, these changes in arterial pressure did not present any clinical relevance, which is in agreement with other studies. 27, 35, 54 In this sense, however, these changes were probably a result of the rapid vasodilating effect of magnesium sulfate. In the salbutamol group, in turn, there was a decrease in respiratory frequency and SAP and, after one hour, an even greater decrease in respiratory frequency. It is highly possible that salbutamol increases tidal volume and, consequently, improves oxygenation of asthmatic patients, reducing tachypnea. Controlled study on intravenous magnesium sulfate...
-Santana JC et alii
After one hour of infusion of drugs, we observed that all three groups presented improvement of tachypnea, but with statistically significant differences between salbutamol and placebo patients (46 vs. 55 breaths/minute, respectively; P=0.02). The poorly significant decrease in respiratory frequency of magnesium sulfate patients and the improvement of respiratory status of intravenous salbutamol patients have also been described elsewhere. 5, 27, 30, 35, [53] [54] [55] [56] [57] This suggests that the studied drugs play an important role in the management of severe acute asthma; in this sense, our findings also suggest that intravenous salbutamol produces more rapid effects and is more effective, considering that the decrease in tachypnea may reflect an increase in tidal volume and improvement in oxygenation.
As to cardiac frequency, we did not observe significant changes before, during, or after infusion of any of the drugs tested. All groups presented higher tachycardia during administration of the drugs; differences in tachycardia were not statistically significant. Few studies have demonstrated interest on monitoring cardiac frequency in patients administered magnesium sulfate. This is because, in general, this drug does not affect cardiac chronotropism. 27, 29, 35, 54 The most serious adverse effect of the use of intravenous salbutamol is tachycardia. Onset of tachycardia is an additional clinical factor to be considered in decrease or termination of use of the drug. Most studies on salbutamol have made reference to its influence on cardiac chronotropism and rhythm, with results as high as 15% increase in initial cardiac frequency that can remain stable even with later increase in dosages. 2, 5, 18, 30 There were also no significant changes in arterial oxygen saturation (SaO 2 ) before, during, or after infusion of drugs. Since asthma is essentially a hypoxemic disease, the mainstay is oxygentherapy. Moreover, considering that patients are clinically similar to each other, the oxymetry results were also similar, as expected. 1, 2, 27, 30, 42, 58, 59 Serum potassium, magnesium, and calcium levels of all patients in our study were measured before and after administration of the drugs. Potassium levels decreased significantly one hour after intravenous salbutamol, but with no clinical relevance. Hypocalcemia has been reported as a frequent clinical finding among children submitted to continuous and intravenous use of salbutamol. Magnesium sulfate and placebo did not affect potassium concentrations. In turn, magnesium levels increased significantly one hour after administration of magnesium sulfate. Magnesium serum did not change significantly in the salbutamol or placebo group. The studied drugs did not affect calcium levels. 5, 21, 35 Arterial gasometry of our patients presented initial average pH indicating clinically overt acidosis. However, after one hour of conventional treatment and infusion of the adjuncts, we verified that acidosis persisted only in the placebo group. Both magnesium sulfate and salbutamol helped to normalize the pH of children in our study. Good clinical response to the administered drugs can also be observed in the concomitant changes in PaCO 2 levels. Initially, we observed a generalized decrease in PaCO 2 probably due to tachypnea, which is a compensatory mechanism of concomitant metabolic acidosis. On the one hand, one hour after infusion, we observed that the placebo group remained with low average PaCO 2 (32.38 ± 3.88 mmHg). On the other hand, patients who had been administered magnesium sulfate or salbutamol already presented an average PaCO 2 within normal levels. Other authors have also described the effects of rapid infusion of magnesium sulfate and salbutamol on compensatory mechanisms of acidosis in children with severe asthma. 27, 35 We also assessed the possible adverse effects of the drugs tested. The magnesium sulfate group presented tachycardia (n=3), facial redness (n=2), and shaking (n=1). The salbutamol group presented tachycardia (n=5) and hypocalcemia (n=1). Most studies on use of magnesium sulfate on acute asthma have not reported adverse or toxic effects of the drug. However, facial redness, discomfort, nausea, vomit, tachycardia, premature ventricular contraction, palpitation, shaking, psychomotor agitation, cephalea, insomnia, and hyperglycemia have been described. 5, 9, 21, 27, 29, 54, 60, 61 In order to assess rapid administration of salbutamol and magnesium sulfate as adjuncts to conventional acute asthma therapy, we registered the total days of use of oxygen and corticosteroid and the amount of nebulizations with bronchodilator. The intravenous salbutamol group required less nebulizations than the placebo group (37 ± 23.6 vs. 68.1 ± 35.5 nebulizations, respectively; P=0.009). In this sense, they also had less nebulizations per day of hospitalization (8.1 ± 1.3 vs. 10.7 ± 1.7 nebulizations per day, respectively; P less than 0.001). Browne et al., while assessing children with acute asthma, observed that the recovery time (time to cessation of nebulized salbutamol every 30 min) was 8.8 hours for patients submitted to the standard protocol, and 1.7 hours for patients submitted to intravenous salbutamol associated with standard protocol (OR 7.0; CI 0.7-13.4; P=0.03). Also, nebulizations in onehour intervals were suspended, in average, after 21 hours of conventional treatment and after 11.5 hours of alternative treatment (OR 9.7; CI 2.0-17.4; P=0.02). 5 Browne et al. also observed that patients with rapid infusion of salbutamol needed less oxygen in comparison to patients with standard protocol (14% vs. 53%; P=0.05). 5 In our study, patients administered intravenous salbutamol as an adjunct to conventional treatment required less oxygentherapy (2.7 ± 1.2 days; P=0.04) in comparison to those administered magnesium sulfate (4.2 ± 2.2 days) and placebo (4.4 ± 2.3 days). Duration of use of corticosteroids was also shorter in the salbutamol group; however, despite the possible clinical significance of this difference, it was not statistically significant in relation to the other groups (P=0.06). A larger study population might have allowed us to show that the use of salbutamol would also reduce the duration of corticotherapy in acute asthma. Still, it is possible that the action of intravenous salbutamol contributed to earlier reversion of hypoxemia and of symptoms resulting from this pathophysiological alteration, allowing these patients to require less oxygen.
Apparently, intravenous beta-2 adrenergics allow for more rapid and greater bronchodilation than that of nebulized administration. Studies have shown that after 2 hours of nebulized beta-2 adrenergics serum concentrations of the drug varied from 20 to 40 ng/ml; in other words, the same plasmatic level attained after 10 minutes of intravenous salbutamol at 1 to 5 micrograms/kg/min. 5, 62, 63 In acute asthma, the effect of drugs on small airways is mild. In our study, children administered intravenous salbutamol needed less oxygentherapy and less nebulized bronchodilators, suggesting a possible relation between early administration of salbutamol and improvement of clinical status. Bronchodilation appears to be the therapeutic result of systemic absorption of the drug that, via blood circulation, reaches the pertinent receptors onto which it will act. 5, 63 This explains the routine use of intravenous salbutamol in pediatric intensive care of children with severe acute asthma who present poor response to standard protocols and are at risk for respiratory failure. 5, 61, 63 The outcome of patients in our population was similar between groups. Frequent clinical complications included pneumonia (28%), sinusitis (18%), and otitis media (14%). Mechanical ventilation was required in 5 (10%) patients, which is in agreement with percentages reported worldwide (0.1 to 33% of children with severe asthma). 8, 13, 15, 30, 43, 61, 64 All patients in our study were discharged from the hospital, which corroborates the findings of other studies on severe asthma in childhood. 1, 13, 20, 27 Intravenous magnesium sulfate and salbutamol were effective and safe for early treatment of acute asthma in childhood; however, salbutamol was therapeutically more effective than magnesium sulfate and, evidently, than placebo. That is because in addition to rapid action of this drug, it was also related with decrease in (i) need for nebulization with beta-2 adrenergics, in (ii) nebulizations per day of hospital stay, and in (iii) duration of oxygentherapy. The main adverse effect of the drug was tachycardia, which only occurred during infusion of the drug and was immediately reversible after suspension of the treatment.
The early use of salbutamol in severe acute asthma of childhood potentially shortens the duration of attacks and lessens their severity; moreover, it also decreases the need for nebulized beta-2 adrenergics. In conclusion, the use of
